Exact Sciences announces improved accuracy of second-generation Cologuard test

seekingalpha2022-01-19

Exact Sciences (NASDAQ:EXAS) announces improved accuracy of its second-generation Cologuard test, a non-invasive stool DNA test used to screen people for colorectal cancer (NYSE:CRC). The test showed...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2204087568?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-19 06:35","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2204087568","market":"us","top_or_hot":-1,"title":"Exact Sciences announces improved accuracy of second-generation Cologuard test","media":"seekingalpha","content":"<div>\n<p>Exact Sciences (NASDAQ:EXAS) announces improved accuracy of its second-generation Cologuard test, a non-invasive stool DNA test used to screen people for colorectal cancer (NYSE:CRC).  The test showed...</p>\n\n<a href=\"https://seekingalpha.com/news/3789001-exact-sciences-announces-improved-accuracy-of-second-generation-cologuard-test\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences announces improved accuracy of second-generation Cologuard test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences announces improved accuracy of second-generation Cologuard test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-19 06:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3789001-exact-sciences-announces-improved-accuracy-of-second-generation-cologuard-test><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exact Sciences (NASDAQ:EXAS) announces improved accuracy of its second-generation Cologuard test, a non-invasive stool DNA test used to screen people for colorectal cancer (NYSE:CRC).  The test showed...</p>\n\n<a href=\"https://seekingalpha.com/news/3789001-exact-sciences-announces-improved-accuracy-of-second-generation-cologuard-test\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://seekingalpha.com/news/3789001-exact-sciences-announces-improved-accuracy-of-second-generation-cologuard-test","article_id":"2204087568","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2204087568","pubTimestamp":1642545312,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Exact Sciences (NASDAQ:EXAS) announces improved accuracy of its second-generation Cologuard test, a ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学","BK4548":"巴美列捷福持仓","BK4139":"生物科技"},"translate_title":"Exact Sciences宣布提高第二代Cologuard测试的准确性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":1},"content_text":"Exact Sciences (NASDAQ:EXAS) announces improved accuracy of its second-generation Cologuard test, a non-invasive stool DNA test used to screen people for colorectal cancer (NYSE:CRC).  The test showed overall sensitivity of 95.2% for CRC at specificity of 92.4% for negative samples confirmed by colonoscopy.  Subgroup analyses showed 83.3% sensitivity for high-grade dysplasia and 57.2% for all advanced precancerous lesions.  A multi-center pivotal trial evaluating second-generation Cologuard markers is ongoing, and results are expected late 2022 or early 2023. EXAS plans to use results of the ongoing trial to support an FDA submission and approval, and make the enhanced Cologuard test available broadly. If approved, the Cologuard test could help increase screening rates, while sending fewer people to follow-up colonoscopies unnecessarily and identifying more advanced precancers before they progress to cancer.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2204087568"}